AC Immune SA (ACIU)

Market Cap	204.81M
Revenue (ttm)	32.01M
Net Income (ttm)	-58.92M
Shares Out	98.94M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,854
Open	2.050
Previous Close	2.070
Day's Range	2.020 - 2.140
52-Week Range	1.430 - 4.260
Beta	1.62
Analysts	Strong Buy
Price Target	12.00 (+479.71%)
Earnings Date	Aug 5, 2025

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 23, 2016
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: ACIU
• Website: https://www.acimmune.com

Financial Performance

In 2024, AC Immune's revenue was 27.31 million, an increase of 84.51% compared to the previous year's 14.80 million. Losses were -50.92 million, -6.12% less than in 2023.

Financial numbers in CHF

Analyst Summary

According to one analyst, the rating for ACIU stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(479.71% upside)

Analyst Consensus: Strong Buy